Through dynamic monitoring of functional sPD-L1 and cytokines in NSCLC patients treated with anti-PD-1 mAbs, it was found that the dynamic changes in sPD-L1 and IL-8 in PD patients were different from those in PR patients; both changes were consistent with tumor load. The gene discussed is CXCL8; the disease is non-small cell lung carcinoma.